Overview

Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 different dose levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Sonexa Therapeutics, Inc.